The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new single-dose 7.2mg pen of Wegovy for the treatment of adult patients living with obesity, marking a significant step forward in weight management therapies. The approval was granted on April 14, 2026.

The newly approved formulation enables patients to receive the maximum weekly dose of 7.2mg through a single injection, offering a more convenient alternative to previous dosing methods. Earlier, patients requiring the highest dose had to administer three separate 2.4mg injections on the same day using the standard pen.

This development is expected to improve treatment adherence and ease of use for patients with a Body Mass Index (BMI) of 30kg/m² or higher. However, the approval does not extend to individuals who are overweight with a BMI below 30kg/m² using the drug solely for weight management, or those taking it to reduce the risk of serious cardiovascular conditions.

Treatment with Wegovy follows a gradual dosing schedule, starting at 0.25mg per week and increasing incrementally every four weeks, based on clinical guidance, until the maximum weekly dose of 7.2mg is reached. Healthcare professionals are advised to closely monitor patients throughout the treatment process.

The MHRA emphasised that patients must use the medication strictly as prescribed and consult their doctor, pharmacist, or nurse if they have any concerns. The regulator also confirmed that it will continue to monitor the safety and effectiveness of the drug.

Patients experiencing potential side effects are encouraged to report them through the MHRA’s Yellow Card scheme, available online and via mobile applications, to ensure ongoing pharmacovigilance.